poisar

Stocks · News reference

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643

Fiscal.ai

BlossomHill Therapeutics has entered into a collaboration with Foundation Medicine to develop a companion diagnostic test for the EGFR C797S mutation in non-small cell lung cancer (NSCLC).

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading